.png)
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company focused on serving patients with ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. It developed and markets Soliris® as a treatment for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Alexion is developing other innovative product candidates, including asfotase alfa, an enzyme replacement therapy for patients with hypophosphatasia (HPP), an ultra-rare, genetic, life-threatening metabolic disease.